Journal of Parasitic Diseases: Diagnosis and Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (629)348-3199

Perspective - Journal of Parasitic Diseases: Diagnosis and Therapy (2025) Volume 10, Issue 3

Therapeutic Interventions in Parasitology: Advancing Strategies for Effective Management of Parasitic Diseases

Lina Chen*

School of Public Health, Peking University, China

Corresponding Author:
Lina Chen
School of Public Health,
Peking University,
China
E-mail: lina.chen@bjmu.edu.cn

Received: 02-Aug-2025, Manuscript No. AAPDDT-25-166524; Editor assigned: 03-Aug-2025, AAPDDT-25-166524 (PQ); Reviewed: 17-Aug-2025, QC No. AAPDDT-25-166524; Revised: 22-Aug-2025, Manuscript No. AAPDDT-25-166524 (R); Published: 30-Aug-2025, DOI:10.35841/2591-7846.10.3.230

Citation: Chen L. Therapeutic interventions in parasitology: advancing strategies for effective management of parasitic diseases, J Parasit Dis Diagn Ther. 2025; 10(3):230

Introduction

Parasitic diseases remain a significant global health challenge, particularly in low- and middle-income countries. Despite advances in diagnostics, therapy remains the cornerstone of parasite control and eradication. This perspective explores current and emerging therapeutic strategies in parasitology, the challenges posed by drug resistance, and the future direction of novel therapies, including host-targeted approaches, nanomedicine, and vaccine development. A multidisciplinary and innovation-driven approach is crucial to achieving long[1]term control and elimination of parasitic diseases. Parasitic infections such as malaria, leishmaniasis, schistosomiasis, and filariasis affect millions worldwide, leading to severe health and economic burdens. While preventative measures and vector control are essential [1, 2, 3, 4].

Emerging Therapeutic Approaches Drug Repurposing Repurposing existing drugs approved for other indications (e.g., antibiotics, anticancer drugs) offers a cost-effective and time-saving approach. For instance, miltefosine, originally developed for cancer, is now used in leishmaniasis treatment. Nanomedicine and Targeted Drug Delivery Nanoparticle-based formulations enhance drug solubility, bioavailability, and targeted delivery. These systems minimize off-target toxicity and improve efficacy, particularly in intracellular parasites such as Toxoplasma gondii and Plasmodium species. Immunotherapy and Host-Directed Therapy Modulating the host immune response to better combat parasitic infections is a promising strategy. Therapies that enhance macrophage activation or cytokine modulation show potential in diseases like leishmaniasis and schistosomiasis. Vaccine Research and Preventive Therapy While no fully effective vaccines exist for most human parasitic diseases, several candidates are under clinical evaluation. RTS,S/AS01, the malaria vaccine, is a landmark development. Continued investment in vaccine development, especially for neglected tropical diseases (NTDs), is imperative for long[1]term disease control. Challenges and Future Directions Drug Resistance: Addressing multidrug-resistant strains requires global surveillance, rational drug use, and development of new mechanisms of action. Effective therapeutic interventions remain critical for disease management and control. However, the emergence of drug-resistant parasites, lack of vaccines for many parasitic diseases, and limited treatment options necessitate innovative and adaptable therapeutic strategies [5, 6].

Conventional Antiparasitic Therapy Traditional antiparasitic drugs such as chloroquine, albendazole, praziquantel, and metronidazole have long been used as first-line treatments. While effective, their widespread and prolonged use has contributed to the development of resistance, particularly in malaria (Plasmodium falciparum) and leishmaniasis (Leishmania donovani). Monotherapy approaches are increasingly insufficient, highlighting the need for combination regimens and novel drug development [7, 8, 9, 10].

Conclusion

Therapeutic interventions in parasitology are at a pivotal point. Traditional drugs, while still relevant, must be supplemented by innovative approaches such as nanomedicine, host-directed therapy, and vaccine development. Limited Pipeline: Investment in parasitology R&D is comparatively low; public-private partnerships can stimulate innovation. Diagnostic Integration: Therapies must be linked with rapid, accurate diagnostics for timely and precise treatment. One Health Approach: Integration of human, animal, and environmental health perspectives can lead to better understanding and control of zoonotic parasitic infections. Collaborative research, increased funding, and integrated public health strategies will be essential to effectively tackle parasitic diseases and reduce their global impact.

References

  1. Ahmad-Mansour N, Loubet P, Pouget C, et al. Staphylococcus aureus toxins: an update on their pathogenic properties and potential treatments. Toxins. 2021;13(10):677.

    2. Indexed at, Google Scholar, Cross Ref

  2. Loh E, Righetti F, Eichner H, et al. RNA thermometers in bacterial pathogens. Microbiol Spectr. 2018;1:55-73.

    3. Indexed at, Google Scholar, Cross Ref

  3. Schröter L, Dersch P. Phenotypic diversification of microbial pathogens—cooperating and preparing for the future. J Mol Biol. 2019;431(23):4645-55.

    4. Indexed at, Google Scholar, Cross Ref

  4. Weinert LA, Welch JJ. Why might bacterial pathogens have small genomes?. Trends Ecol Evol. 2017;32(12):936-47.

    5. Indexed at, Google Scholar, Cross Ref

  5. Sheppard SK. Strain wars and the evolution of opportunistic pathogens. Curr Opin Microbiol. 2022;67:102138.

    6. Indexed at, Google Scholar, Cross Ref

  6. Roussin-Léveillée C, Mackey D, Ekanayake G, et al. Extracellular niche establishment by plant pathogens. Nat Rev Microbiol. 2024;22(6):360-72.

    7. Indexed at, Google Scholar, Cross Ref

  7. RoyChowdhury M, Sternhagen J, Xin Y, et al. Evolution of pathogenicity in obligate fungal pathogens and allied genera. Peer J. 2022;10:e13794.

    8. Indexed at, Google Scholar, Cross Ref

  8. Banerji R, Kanojiya P, Patil A, et al. Polyamines in the virulence of bacterial pathogens of respiratory tract. Mol Oral Microbiol. 2021;36(1):1-1.

    9. Indexed at, Google Scholar, Cross Ref

  9. Saur IM, Hückelhoven R. Recognition and defence of plant-infecting fungal pathogens. J Plant Physiol. 2021;256:153324.

    10. Indexed at, Google Scholar, Cross Ref

  10. Leitão JH. Microbial virulence factors. Int J Mol Sci. 2020;21(15):5320.

    11. Google Scholar

Get the App